A patient-centric benefit-risk assessment of daridorexant for the treatment of insomnia disorder using patient preference data collected in two phase 3 clinical trials

Authors: Sebastian Heidenreich, Melissa Ross, Bruno Flamion et al.
Publication: Sleep Epidemiology
Published: Dec 1, 2025
Source: Crossref
Back to Search View Original Cite This Article

Related Articles

Assessment of Human Health Risk and Surface Soil Contamination by Some Toxic Elements in Arak City, Iran

Meghdad Bineshpour, Khoshnaz Payandeh et al. - Oct 2121

Read More
Investigating the Non-carcinogenic Risk and Hazard Quotient of Heavy Metals in High-traffic Districts of Tehran Metropolis, Iran

Azam Mahdipour, Mojgan Zaeimdar et al. - Oct 2121

Read More
Investigation and Optimization of Air Pollution Risk by a Multi-criteria Decision Making Method Using Fuzzy TOPSIS: A Case Study of Construction Workers

Eghbal Sekhavati, Reza Jalilzadeh Yengejeh - Oct 2121

Read More
The Effects of Relaxing Music on Life Distress and Maternal-fetal Attachment in Pregnant Women

Mona Shokri Shams, Anahita Khodabakhshi-Koolaee et al. - Feb 2121

Read More
PERSONALIZED SELF-ASSESSMENT FOR DEAF AND HARD–OF–HEARING STUDENTS

Catherine Marinagi, Fotini Sarinopoulou et al. - Dec 2114

Read More